The IVNS1ABP Knockout HEK293T Polyclonal Cells product comprises a population of human embryonic kidney 293T cells engineered to carry a CRISPR/Cas9-mediated disruption of the IVNS1ABP gene locus. This polyclonal knockout model provides a genetically heterogeneous pool of edited cells, enabling robust loss-of-function studies without clonal selection artifacts. The gene editing approach introduces targeted disruptions in IVNS1ABP, abolishing its expression and functional output across the cell population, thereby facilitating investigation of its roles in RNA processing and cytoskeletal regulation.
HEK293T cells, derived from the parental HEK293 line, constitutively express the SV40 large T antigen, which promotes episomal replication of plasmids containing the SV40 origin of replication. This feature, combined with their high transfection efficiency, makes HEK293T cells a versatile and widely used host for protein expression, lentivirus production, and transient or stable gene manipulation. The cell line??s embryonic kidney origin provides a relevant epithelial background for studying cellular pathways, while its robust growth characteristics and compatibility with various molecular biology techniques simplify experimental workflows.
IVNS1ABP (Influenza Virus NS1A Binding Protein) functions as a critical regulator of pre-mRNA splicing and cytoskeletal dynamics. It directly interacts with components of the spliceosome, including PRPF8, and associates with the actin cytoskeleton, linking RNA processing to cellular architecture. The protein also binds the influenza A virus non-structural protein 1 (NS1), which sequesters IVNS1ABP to disrupt host mRNA processing and facilitate viral mRNA export and replication. In the signaling network, IVNS1ABP acts downstream of NS1-mediated post-translational interference and upstream of alternative splicing events and actin filament organization. Representative pathway components affected by IVNS1ABP include spliceosomal factors SNRNP200 and mRNA export factor NXF1, as well as cytoskeletal proteins such as actin. The mechanistic interplay positions IVNS1ABP at a hub connecting viral subversion pathways and fundamental cellular processes.
In the HEK293T background, the IVNS1ABP knockout model offers a defined system to dissect how loss of this splicing and cytoskeletal regulator impacts host cell physiology and influenza virus replication. Because HEK293T cells support efficient viral replication and can be readily transfected with viral components, this polyclonal knockout population is particularly suited for examining NS1-mediated perturbations in a simplified, controllable setting. The model allows researchers to decouple IVNS1ABP-dependent splicing changes from cytoskeletal phenotypes and to assess whether these pathways converge during viral infection. Moreover, the high transfection efficiency of HEK293T cells enables complementation experiments with wild-type or mutant IVNS1ABP constructs to validate functional domains.
This product is designed for a range of advanced applications, including mechanistic studies of influenza virus?Chost interactions, analysis of alternative splicing regulation, and investigation of cytoskeleton-linked signaling. Researchers can employ co-immunoprecipitation and Western blotting to verify loss of IVNS1ABP protein and altered interaction with PRPF8 or actin; RT-qPCR and transcriptomic analyses to profile splicing changes; and immunofluorescence to visualize cytoskeletal reorganization. Viral replication assays in the knockout background can quantify the role of IVNS1ABP in supporting or restricting influenza infection. These polyclonal knockout cells also serve as a foundational tool for CRISPR functional validation screens. For additional information or to discuss custom requirements, please contact Ascent Research.
